



Accelerating early phase oncology studies with a specialized global site network

Fortrea's EPON is a curated network of early phase capable Oncology Sites that deliver predictable speed and uncompromising quality, giving sponsors streamlined access to clinical trial centers with expertise in niche and complex modalities, from advanced therapies such as Cell and Gene Therapies to Antibody drug conjugates (ADCs).

Meeting the demands of modern oncology trials

Early phase oncology trials today are increasingly more complex, driven by adaptive designs, biomarker enriched cohorts and novel modalities. Urgent cancer patient needs and scientific innovation demand more than a standard CRO approach.

Fortrea EPON is built for this new era

Fortrea has hand-selected specialized sites in strategic geographic locations and works closely with them. Over the years, we have gained deep insight into their capabilities and know how to leverage their strengths to meet each study's unique needs in the best possible way.

We solve the most common challenges in early-phase oncology research by delivering:

- **Predictable and reliable timelines:** Consistent study start-up and enrollment, through streamlined processes and master agreements
- **Uncompromising data quality:** High data integrity, robust patient retention and consistent achievement of KPIs
- **Streamlined access:** Direct connection to niche and complex oncology modalities, including advanced therapies and rare indications
- **Early visibility of clinical development programs**


With EPON, sponsors gain a strategic ally ready to deliver results in the most challenging and innovative areas of oncology research.

Predictable speed

Uncompromising quality

Access to world-class clinical research capabilities

Our global footprint: Over 70 EPON partners worldwide



North
America
23

Europe
49

South
America
4

APAC
11

...and growing

Fortrea EPON performance at a glance

Accelerated start-up: Consistently shorter activation timelines across all major regions
Sites with proven start-up strength

U.S. 5-8 weeks	Europe 10-12 weeks
-------------------	-----------------------

Quality you can trust: High data integrity, rapid query resolution (<10 days) and strong patient retention

Consistent achievement of enrolment commitments: Robust performance against KPIs and reliable delivery for sponsors

Enrollment and screening rate EPON sites: >22% higher than non-EPON sites
Median enrollment rate

EPON 0.25–0.27 patients/site/month	Non-EPON 0.17–0.21 patients/site/month
---------------------------------------	---

Consistent enrollment targets

Reliable achievement of enrollment goals



Accelerated enrollment

Faster patient recruitment for clinical trials

Superior data quality


High-quality and reliable data collection



Rapid start-up timelines

Quick initiation of clinical studies

Strategic site mix: Choosing the right sites for the right impact



Case studies: EPON impact in action

Case study 1:

Speed and reliability in site activation

A global sponsor needed to launch a complex early phase oncology trial with tight timelines and high expectations.

"EPON site activated in six weeks from initial contact, compared to industry average of 12 weeks."

"First patient enrolled within four weeks of site activation, exceeding sponsor expectations."

The sponsor faced industry-standard delays and was concerned about missing critical milestones. By leveraging EPON's pre-established agreements and dedicated relationship managers, the site was activated in record time and patient recruitment began almost immediately—demonstrating EPON's ability to deliver predictable speed and reliability.

Case study 2:

Collaborative protocol optimization

A sponsor's protocol for a biomarker-driven cohort was struggling to attract eligible patients.

"Site feedback led to protocol amendments that improved patient eligibility and recruitment rates."

"Sponsor reported a 25% increase in enrollment after protocol changes suggested by EPON site investigators."

EPON's model of early engagement and scientific partnership enabled site investigators to provide actionable feedback. The protocol was amended to better reflect real-world patient profiles, resulting in a significant boost in recruitment and overall study success.

Four pillars of advantage

Integrated global expert early phase site network

A global network of early phase-capable oncology sites, handpicked for their skill in complex, first-in-human clinical trials involving innovative, often first-in-class therapies.

Collaborative clinical partnerships

Co-led by Site Partnerships, Oncology Medics and local clinical resources foster strong clinical relationships and strategic collaboration, ensuring credible dialogue and stable, long-term partnerships that accelerate consistent, high-quality study delivery.

Leveraging site level clinical and operational knowledge

Sites actively shape study strategies through early, evidence-driven feedback—enabling sponsors and Fortrea to optimize protocols and enhance feasibility.
The result: Contemporary design recommendations, faster execution and better outcomes for all stakeholders, especially patients.

Expanded therapeutic reach

Select EPON sites extend their capabilities beyond early-phase oncology into late-phase and adjacent indications, including autoimmune and rare diseases.



Ready to accelerate your oncology program?

Partner with EPON and experience the difference that operational precision, scientific insight and global reach can make for your early phase trials.

Contact us today to discuss your next study and discover how EPON can deliver speed, quality and results.

**Fortrea’s EPON: Where innovation meets execution.
Delivering hope, together.**

Explore Fortrea Oncology

Scan to visit our oncology expertise and site network.



Exceptional is possible.

Harnessing our passion for scientific rigor and decades of clinical trial experience, we're looking to navigate obstacles with agility and ease. We are problem solvers and creative thinkers committed to opening the doors between promising ideas and proven therapies.



LEARN MORE at fortrea.com

